文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症

雾化与静脉氨甲环酸治疗咯血:一项先导性随机对照试验

Nebulized vs IV Tranexamic Acid for Hemoptysis: A Pilot Randomized Controlled Trial.
PubMed 文献 · Chest · 2022-11-19
一句话结论在急诊轻症咯血患者中,雾化氨甲环酸较静脉给药可能更有效减少咯血量及介入操作需求,但需更大样本研究验证。

该先导性随机对照试验纳入急诊活动性咯血成人患者,比较雾化氨甲环酸(500 mg tid)与静脉氨甲环酸(500 mg tid)。主要终点为给药后30分钟止血,雾化组显著高于静脉组(40例 vs 28例,P = .0019)。雾化组在各观察时点咯血量均显著减少,需支气管动脉栓塞者更少(13例 vs 21例,P = .024),急诊离院率更高(67.92% vs 39.02%,P = .005)。雾化组2例出现无症状支气管痉挛,经短效β受体激动剂雾化后缓解。作者认为雾化氨甲环酸可能更有效,但需未来更大规模研究进一步探索。

要点

  • 急诊成人活动性咯血患者中,雾化氨甲环酸500 mg tid较静脉500 mg tid显著提高30分钟止血率(40/55 vs 28/55,P = .0019)。
  • 雾化组在30分钟、6小时、12小时、24小时的咯血量均显著低于静脉组(P值分别为.011、.002、.0008、.005)。
  • 雾化组需支气管动脉栓塞者更少(13例 vs 21例,P = .024),急诊离院率更高(67.92% vs 39.02%,P = .005)。
  • 雾化组2例出现无症状支气管痉挛,经短效β受体激动剂雾化后缓解。
  • 血流动力学不稳定、需立即介入操作或机械通气的患者被排除。

适用人群与场景

  • 急诊就诊的成人活动性咯血患者。
  • 排除血流动力学不稳定、需立即介入操作或机械通气的患者。

处置流程与药物剂量

  • 雾化氨甲环酸500 mg tid。
  • 静脉氨甲环酸500 mg tid。

研究设计与关键结果

  • 研究类型:实用性、开放标签、随机、平行、单中心先导试验;每组55例。
  • 主要终点:给药后30分钟止血率雾化组40例 vs 静脉组28例(χ2(1, n=110)=5.55;P = .0019)。
  • 次要终点:咯血量减少在各观察时点均为雾化组显著更优(30分钟 P = .011,6小时 P = .002,12小时 P = .0008,24小时 P = .005)。
  • 需支气管动脉栓塞者雾化组13例 vs 静脉组21例(P = .024)。
  • 急诊离院率雾化组67.92% vs 静脉组39.02%(P = .005)。
  • 不良事件:雾化组2例出现无症状支气管痉挛,经短效β受体激动剂雾化后缓解;急诊离院患者在72小时随访期内均未接受介入操作或因再出血重返急诊。

证据类型、等级与局限

  • 证据类型:先导性随机对照试验。
  • 局限:作者指出需未来更大规模研究进一步探索雾化氨甲环酸与静脉氨甲环酸在轻症咯血患者中的潜力。

对床旁实践的改变

  • 作者认为,雾化氨甲环酸可能较静脉氨甲环酸更有效减少咯血量及急诊介入操作需求。
  • 适用人群为急诊活动性咯血成人患者,排除血流动力学不稳定、需立即介入操作或机械通气者。
  • 雾化组2例出现无症状支气管痉挛,经短效β受体激动剂雾化后缓解。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Tranexamic acid (TA) is used to control bleeding in patients with hemoptysis. However, the effectiveness of the different routes of TA administration has not been studied.

RESEARCH QUESTION: Does the nebulized route of TA administration reduce the amount of hemoptysis compared with the IV route in patients presenting to the ED with hemoptysis?

STUDY DESIGN AND METHODS: This was a pragmatic, open-label, randomized, parallel, single-center, pilot trial of nebulized TA (500 mg tid) vs IV TA (500 mg tid) in adult patients presenting to the ED with active hemoptysis. The primary outcome was cessation of bleeding at 30 min. Secondary outcomes included amount of hemoptysis at 6, 12, and 24 h; interventional procedures; and side effects of TA. Patients who were hemodynamically unstable or requiring immediate interventional procedure or mechanical ventilation were excluded from the study.

RESULTS: Of the 55 patients in each arm, hemoptysis cessation at 30 min following TA administration was significantly higher in the nebulization arm (n = 40) compared with the IV arm (n = 28): χ2 (1, n = 110) = 5.55; P = .0019. Also, hemoptysis amount was reduced significantly in the nebulization arm at all time periods of observation (P value at 30 min = .011, at 6 h = .002, 12 h = .0008, and at 24 h = .005). Fewer patients in the nebulization arm required bronchial artery embolization (13 vs 21; P = .024) and thereby had higher discharge rates from the ED (67.92% vs 39.02%; P = .005). Two patients in the nebulization arm had asymptomatic bronchoconstriction that resolved after short-acting beta-agonist nebulization. No patient discharged from the ED underwent any interventional procedure or revisited the ED with rebleed during the 72 h follow-up period.

INTERPRETATION: Nebulized TA may be more efficacious than IV TA in reducing the amount of hemoptysis and need for ED interventional procedures. Future larger studies are needed to further explore the potential of nebulized TA compared with IV TA in patients with mild hemoptysis.

CLINICAL TRIAL REGISTRATION: Clinical Trials Registry-India; No.: CTRI/2019/05/019337; URL: http://ctri.nic.in/Clinicaltrials/advancesearchmain.php.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Gopinath B, Mishra PR, Aggarwal P, et al. Nebulized vs IV Tranexamic Acid for Hemoptysis: A Pilot Randomized Controlled Trial. Chest. 2022. PMID: 36410494. doi:10.1016/j.chest.2022.11.021

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。